EAEvana Akhtar

Evana Akhtar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Evana Akhtar has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Defining Reference Intervals for Complete Blood Count and Micronutrient Parameters in Urban Bangladeshi Population

    by Md. Ahsanul Haq, Kiyoshi Ichihara, Dewan Zubaer Islam, Md. Jakarea, Mohammad Mehedi Hasan, Anjan Kumar Roy, Evana Akhtar, Rubhana Raqib, Protim Sarker

    With a lack of population-specific reference intervals (RIs) in Bangladesh, this study aimed to determine RIs for complete blood count (CBC) and specific micronutrients, vitamin D (VitD) and zinc, and to assess the possible impact of prior history of SARS-CoV-2 infection on these parameters. Healthy participants (n = 1724) of both sexes aged ≥ 10 years from slum and non-slum areas of Dhaka city were sampled systematically. A total of 26 CBC parameters were determined using an automated hematology analyzer, whereas the micronutrients VitD and zinc were measured using automated immunoassay analyzers and atomic absorption spectrophotometry (AAS), respectively. Multiple regression analysis (MRA) was employed to determine the association of variations in reference values (RVs) of hematological and micronutrient parameters with sex, age, and slum residency of the participants. Practical significance of each factor was judged from partial correlation coefficients (rp) by setting its minimum effect size at |rp| = 0.2. The need to partition RVs by sex and age was assessed using the ANOVA-based standard deviation ratio (SDR). RIs were determined by parametric method after Gaussian transformation using the two-parameter Box–Cox formula, with or without the latent abnormal values exclusion (LAVE) method. By MRA, sex and age were significant source of variations for various CBC parameters, whereas slum residence was associated with increased levels of VitD and zinc Using the SDR ≥ 0.35 threshold, RVs were partitioned by sex to derive RIs for hemoglobin, hematocrit, red cell count and indices (MCH, MCHC), and plateletcrit, as well as for VitD and zinc. Comparing these RIs with those from the global collaborative studies indicated significant differences in erythrocyte and leukocyte parameters. These are the first population-specific RIs for urban Dhaka city, underscoring the need for country-specific RIs for accurate clinical use.

  • Open Access

    Air Pollution Exposures of Bangladeshi Women from Rural and Peri-Urban Areas: Baseline Assessment for Behavior Change Communication Intervention as a Sustainable Approach

    by Evana Akhtar, Ahsanul Haq, Shamim Hossain, Marzan Sultana, Saira Tasmin, Bilkis Ara Begum, Mahbub Eunus, Golam Sarwar, Faruque Parvez, Habibul Ahsan, et al.

    Building on prior evidence that biomass cooking drives personal air pollution in rural and peri-urban Bangladesh, we measured kitchen pollution alongside personal exposure and examined the influence of outdoor industrial and traffic emissions on personal and indoor air quality. In an mHealth based-behavior change communication (BCC) intervention study (NCT05570552), 400 women were enrolled from rural Matlab and peri-urban Araihazar in Bangladesh. We measured 24 h personal exposure to fine particulate matter 2.5 (PM2.5) and black carbon (BC) using personal monitors (UPAS V2), and 72–120 h PM2.5 in 200 kitchens and outdoors of households using air quality sensors (PurpleAir Flex). Compared to clean fuel users, biomass users showed greater personal and kitchen exposure to PM2.5, showing good correlation between personal and indoor PM2.5 measurements (R2 = 0.722). Daily average personal PM2.5 and kitchen PM2.5 during both cooking and non-cooking periods were higher in rural than peri-urban areas. Geographic information system mapping revealed that personal PM2.5 was inversely related to the distance of factories from households when below p < 0.001). Higher levels of PM2.5 and increased BC were found in rural and peri-urban households, respectively, which were located in close proximities to formal/informal factories and main roads. These findings highlight the need for sustainable household energy transitions and improved air quality management to reduce air pollution exposure in Bangladesh.

  • Open Access

    Factors Associated with Reported COVID-like Symptoms and Seroprevalence Data Matched with COVID-like Symptoms in Slums and Non-Slums of Two Major Cities in Bangladesh

    by Abdur Razzaque, Tarique Mohammad Nurul Huda, Razib Chowdhury, Ahsanul Haq, Protim Sarker, Evana Akhtar, Arif Billah, Mohammad Zahirul Islam, Dewan Md. Emdadul Hoque, Shehlina Ahmed, et al.

    Objectives: To examine the levels and socio-demographic differentials of: (a) reported COVID-like symptoms; and (b) seroprevalence data matched with COVID-like symptoms. Methods: Survey data of reported COVID-like symptoms and seroprevalence were assessed by Roche Elecsys® Anti-SARS-CoV-2 immunoassay. Survey data of 10,050 individuals for COVID-like symptoms and seroprevalence data of 3205 individuals matched with COVID-like symptoms were analyzed using bivariate and multivariate logistic analysis. Results: The odds of COVID-like symptoms were significantly higher for Chattogram city, for non-slum, people having longer years of schooling, working class, income-affected households, while for households with higher income had lower odd. The odds of matched seroprevalence and COVID-like symptoms were higher for non-slum, people having longer years of schooling, and for working class. Out of the seropositive cases, 37.77% were symptomatic—seropositive, and 62.23% were asymptomatic, while out of seronegative cases, 68.96% had no COVID-like symptoms. Conclusions: Collecting community-based seroprevalence data is important to assess the extent of exposure and to initiate mitigation and awareness programs to reduce COVID-19 burden.


  • Open Access

    Antibodies to Commonly Circulating Viral Pathogens Modulate Serological Response to Severe Acute Respiratory Syndrome Coronavirus 2 Infection

    by Protim Sarker, Evana Akhtar, Sharmin Akter, Sultana Rajia, Rakib Ullah Kuddusi, Razu Ahmed, Jakarea, Mohammad Zahirul Islam, Dewan Md Emdadul Hoque, Shehlina Ahmed, et al.

    The purpose of this study was to determine the seropositivity of circulating viral pathogens and their association with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity. In a cross-sectional design, inhabitants (aged 10–60 years) of the slum and surrounding non-slum areas of Dhaka and Chattogram Metropolitan cities in Bangladesh were enrolled from October 2020 to February 2021. Antibodies to SARS-CoV-2, influenza B, parainfluenza, respiratory syncytial virus (RSV), human coronavirus HKU1 (HCoV-HKU1), dengue and chikungunya viruses were determined in plasma. The association of SARS-CoV-2 seropositivity with seropositivity to other viruses was assessed using the multi-variate logistic regression model. Seroprevalence of SARS-CoV-2, influenza B, RSV, dengue, chikungunya, HCoV-HKU1 and the parainfluenza virus were 68.3%, 98%, 50.0%, 16.5%, 15.5%, 3.36% and 0.0%, respectively. Individuals seropositive for RSV had lower odds (OR = 0.60; 95% CI= 0.49, 0.73) of SARS-CoV-2 seropositivity compared to RSV-seronegative individuals. Conversely, higher odds of SARS-CoV-2 seropositivity were observed in participants seropositive for dengue (OR= 1.73; 95% CI = 1.14, 2.66, only in slum) or chikungunya (OR = 1.48; 95% CI = 1.11, 1.95) compared to their seronegative counterparts. The study findings indicated that exposure to vector-borne virus dengue or chikungunya enhance, while antibodies to respiratory virus RSV decrease, the serological response to SARS-CoV-2.


  • Open Access

    Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population

    by Protim Sarker, Evana Akhtar, Rakib Ullah Kuddusi, Mohammed Mamun Alam, Ahsanul Haq, Biplob Hosen, Bikash Chandra Chanda, Farjana Haque, Muntasir Alam, Abdur Razzaque, et al.

    Background: The adaptive immune response is a crucial component of the protective immunity against SARS-CoV-2, generated after infection or vaccination. Methods: We studied antibody titers, neutralizing antibodies and cellular immune responses to four different COVID-19 vaccines, namely Pfizer-BioNTech, Moderna Spikevax, AstraZeneca and Sinopharm vaccines in the Bangladeshi population (n = 1780). Results: mRNA vaccines Moderna (14,655 ± 11.3) and Pfizer (13,772 ± 11.5) elicited significantly higher anti-Spike (S) antibody titers compared to the Adenovector vaccine AstraZeneca (2443 ± 12.8) and inactivated vaccine Sinopharm (1150 ± 11.2). SARS-CoV-2-specific neutralizing antibodies as well as IFN-γ-secreting lymphocytes were more abundant in Pfizer and Moderna vaccine recipients compared to AstraZeneca and Sinopharm vaccine recipients. Participants previously infected with SARS-CoV-2 exhibited higher post-vaccine immune responses (S-specific and neutralizing antibodies, IFN-γ-secreting cells) compared to uninfected participants. Memory B (BMEM), total CD8+T, CD4+ central memory (CD4+CM) and T-regulatory (TREG) cells were more numerous in AstraZeneca vaccine recipients compared to other vaccine recipients. Plasmablasts, B-regulatory (BREG) and CD4+ effector (CD4+EFF) cells were more numerous in mRNA vaccine recipients. Conclusions: mRNA vaccines generated a higher antibody response, while a differential cellular response was observed for different vaccine types, suggesting that both cellular and humoral responses are important in immune monitoring of different types of vaccines.


  • Open Access

    A high-selenium lentil dietary intervention in Bangladesh to counteract arsenic toxicity: study protocol for a randomized controlled trial

    by Regina M. Krohn, Rubhana Raqib, Evana Akhtar, Albert Vandenberg, Judit E. G. Smits

    Millions of people worldwide are exposed to dangerous levels of arsenic (above the WHO water standard of 10 ppb) in drinking water and food. Lack of nutritious foods exacerbates the adverse health effects of arsenic poisoning. The micronutrient selenium is a known antagonist to arsenic, promoting the excretion of arsenic from the body. Studies are in progress examining the potential of using selenium supplement pills to counteract arsenic toxicity. We are planning a clinical trial to test whether high-selenium lentils, as a whole food solution, can improve the health of arsenic-exposed Bangladeshi villagers. A total of 400 participants (about 80 families) will be divided into two groups via computer-generated block randomization. Eligibility criteria are age (≥14) years) and arsenic concentration in the household tube well (≥100 ppb). In this double-blind study, one group will eat high-selenium lentils grown in western Canada; the other will consume low-selenium lentils grown in Idaho, USA. Each participant will consume 65 g of lentils each day for 6 months. At the onset, midterm, and end of the trial, blood, urine and stool, plus hair (day 1 and at 6 months only) samples will be collected and a health examination conducted including assessment of acute lung inflammation, body mass and height, and blood pressure. The major outcome will be arsenic excretion in urine and feces, as well as arsenic deposition in hair and morbidity outcomes as assessed by a biweekly questionnaire. Secondary outcomes include antioxidant status, lipid profile, lung inflammation status, and blood pressure. Selenium pills as a treatment for arsenic exposure are costly and inconvenient, whereas a whole food approach to lower the toxic burden of arsenic may be a practical remedy for Bangladeshi people while efforts to provide safe drinking water are continuing. If high-selenium lentils prove to be effective in counteracting arsenic toxicity, agronomic partnerships between Canada and Bangladesh will work to improve the selenium content of the Bangladeshi-grown lentil crops. Results will be presented to the community to promote informed food choices, which may include increasing selenium in their diet. ClinicalTrials.gov NCT02429921


  • Open Access

    Oral intake of phenylbutyrate with or without vitamin D3upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis

    by Akhirunnesa Mily, Rokeya Sultana Rekha, S M Mostafa Kamal, Evana Akhtar, Protim Sarker, Zeaur Rahim, Gudmundur H Gudmundsson, Birgitta Agerberth, Rubhana Raqib

    Background: We earlier showed that 4-phenylbutyrate (PB) can induce cathelicidin LL-37 expression synergistically with 1,25-dihydroxyvitamin D3 in a lung epithelial cell line. We aimed to evaluate a therapeutic dose of PB alone or in combination with vitamin D3 for induction of LL-37 expression in immune cells and enhancement of antimycobacterial activity in monocyte-derived macrophages (MDM). Methods: Healthy volunteers were enrolled in an 8-days open trial with three doses of PB [250 mg (Group-I), 500 mg (Group-II) or 1000 mg (Group-III)] twice daily (b.d.) together with vitamin D3 {5000 IU once daily (o.d.)}, PB (500 mg b.d.) (Group-IV) or vitamin D3 (5000 IU o.d.) (Group-V), given orally for 4 days. Blood was collected on day-0, day-4 and day-8; plasma was separated, peripheral blood mononuclear cells (PBMC), non-adherent lymphocytes (NAL) and MDM were cultured. LL-37 transcript in cells and peptide concentrations in supernatant were determined by qPCR and ELISA, respectively. In plasma, 25-hydorxyvitamin D3 levels were determined by ELISA. MDM-mediated killing of Mycobacterium tuberculosis (Mtb) (H37Rv) was performed by conventional culture method. Results: MDM from Group-II had increased concentration of LL-37 peptide and transcript at day-4, while Group-I showed increased transcript at day-4 and day-8 compared to day-0 (p < 0.05). Both Group-I and -II exhibited higher levels of transcript on day-4 compared to Group-III and Group-V (p < 0.035). Increased induction of peptide was observed in lymphocytes from Group-II on day-4 compared to Group-I and Group-IV (p < 0.05), while Group-IV showed increased levels on day-8 compared to Group-I and Group-III (p < 0.04). Intracellular killing of Mtb on day-4 was significantly increased compared to day-0 in Group-I, -II and -V (p < 0.05). Conclusion: The results demonstrate that 500 mg b.d. PB with 5000 IU o.d. vitamin D3 is the optimal dose for the induction of LL-37 in macrophages and lymphocytes and intracellular killing of Mtb by macrophages. Hence, this dose has potential application in the treatment of TB and is now being used in a clinical trial of adults with active pulmonary TB (NCT01580007).


  • Open Access

    Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial

    by Daniel E Roth, Abdullah Al Mahmud, Rubhana Raqib, Evana Akhtar, Nandita Perumal, Brendon Pezzack, Abdullah H Baqui

    Antenatal vitamin D status may be associated with the risk of adverse pregnancy and neonatal outcomes; however, the benefits of vitamin D supplementation during pregnancy remain unknown.


  • Open Access

    Pharmacokinetics of High-Dose Weekly Oral Vitamin D3 Supplementation during the Third Trimester of Pregnancy in Dhaka, Bangladesh

    by Daniel E. Roth, Abdullah Al Mahmud, Rubhana Raqib, Evana Akhtar, Robert E. Black, Abdullah H. Baqui

    A pharmacokinetic study was conducted to assess the biochemical dose-response and tolerability of high-dose prenatal vitamin D3 supplementation in Dhaka, Bangladesh (23°N). Pregnant women at 27–30 weeks gestation (n = 28) were randomized to 70,000 IU once + 35,000 IU/week vitamin D3 (group PH: pregnant, higher dose) or 14,000 IU/week vitamin D3 (PL: pregnant, lower dose) until delivery. A group of non-pregnant women (n = 16) was similarly administered 70,000 IU once + 35,000 IU/week for 10 weeks (NH: non-pregnant, higher-dose). Rise (∆) in serum 25-hydroxyvitamin D concentration ([25(OH)D]) above baseline was the primary pharmacokinetic outcome. Baseline mean [25(OH)D] were similar in PH and PL (35 nmol/L vs. 31 nmol/L, p = 0.34). A dose-response effect was observed: ∆[25(OH)D] at modeled steady-state was 19 nmol/L (95% CI, 1 to 37) higher in PH vs. PL (p = 0.044). ∆[25(OH)D] at modeled steady-state was lower in PH versus NH but the difference was not significant (−15 nmol/L, 95% CI −34 to 5; p = 0.13). In PH, 100% attained [25(OH)D] ≥ 50 nmol/L and 90% attained [25(OH)D] ≥ 80 nmol/L; in PL, 89% attained [25(OH)D] ≥ 50 nmol/L but 56% attained [25(OH)D] ≥ 80 nmol/L. Cord [25(OH)D] (n = 23) was slightly higher in PH versus PL (117 nmol/L vs. 98 nmol/L; p = 0.07). Vitamin D3 was well tolerated; there were no supplement-related serious adverse clinical events or hypercalcemia. In summary, a regimen of an initial dose of 70,000 IU and 35,000 IU/week vitamin D3 in the third trimester of pregnancy was non-hypercalcemic and attained [25(OH)D] ≥ 80 nmol/L in virtually all mothers and newborns. Further research is required to establish the safety of high-dose vitamin D3 in pregnancy and to determine if supplement-induced [25(OH)D] elevations lead to maternal-infant health benefits.